As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.
CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage study
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Prostate cancer breakthrough as drug combo gives patients a powerful new chance
ASCO: J&J breaks the prostate cancer treatment mold with fresh Erleada ph. 3 win
‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer
For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death
Hope for thousands as new drug cuts prostate cancer relapse risk
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
The study, which followed patients for over five years, found that those who received the regimen were nine times more likely…
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces…
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery,…
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer…
CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with…
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were…
